Rodrigues Dominic 4
4 · PROVECTUS BIOPHARMACEUTICALS, INC. · Filed Sep 20, 2022
Insider Transaction Report
Form 4
Rodrigues Dominic
Director
Transactions
- Purchase
Series D Convertible Preferred Stock
2022-09-16$0.29/sh+11,416,262$3,267,334→ 11,416,262 totalFrom: 2022-09-16→ Common Stock (11,416,262 underlying)
Footnotes (2)
- [F1]Each share of Series D Convertible Preferred Stock, par value $0.001 per share ("Series D Convertible Preferred Stock") is convertible into one share of the Issuer's common stock, par value $0.001 per share ("Common Stock").
- [F2]The Series D Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D Convertible Preferred Stock.